Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant (Q93328935)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant |
clinical trial |
Statements
A 2-Part, Phase 1/2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-M™ Adjuvant In Healthy Subjects (English)
0 references
1 reference
15 May 2020
0 references
31 December 2020
0 references
131
0 references
1 reference
18 year
0 references
59 year
0 references